|
|
Archive for the ‘Biologics’ Category
January 25th 2012 | Biologics, Patient Stories, Psoriasis Cure Now, Psoriasis Research, psoriatic arthritis, Public policy issues | 4 Comments
Before 2011 becomes a distant memory, Psoriasis Cure Now felt it would be useful to highlight what we believe were the top psoriasis and psoriatic arthritis stories of 2011. The year included bad news about a promising treatment from Abbot buy cialis online uk t, as well as a psoriasis sub-plot to one of the
READ THE FULL POST
March 2nd 2011 | Biologics, Health care system, psoriatic arthritis, Public policy issues | 1 Comment
We’re happy to see the Phil Mickelson psoriasis, psoriatic arthritis, and RA campaign launch. Go Phil! We hope he is winning again soon. The campaign is called On Course with Phil, and you can see the site here:
January 19th 2011 | Biologics, Psoriasis Research, Treatment | 0 Comments
Even treatments that are already approved by the U.S. Food and Drug Administration (FDA) are frequently tested further in clinical trials under close medical supervision. Such trials typically offer free meds and thorough medical screening – a gre WORK FROM NO HOME at deal for patients. Check out our full report on psoriasis research studies
READ THE FULL POST
January 15th 2011 | Biologics, Psoriasis Research, Side-effects of treatment | 13 Comments
Abbott today announced in a securities filing that it has withdrawn its application with the U.S. Food and Drug Administration (FDA) and European regulators to market its much-anticipated, experimental
October 11th 2010 | Biologics, Psoriasis Research, Side-effects of treatment, Treatment | 11 Comments
[UPDATE 1/14/2011: Abbott today announced that it has withdrawn its application with the U.S. FDA to market briakinumab (ABT-874, Ozespa). Our full analysis of Abbott's pulling its briakinumab application is here. Our original, unedited post concerning the Phase Three trials is below.] You know that buzz about Centocor Ortho Biotech’s biologic Stelara (ustekinumab), the first
READ THE FULL POST
October 7th 2010 | Biologics, Psoriasis Research, Treatment | 0 Comments
New data on Stelara (ustekinumab) has been presented at a European scientific meeting, and it shows Stelara performing well for most patients in the clinical trial, even after 2 cheap viagra years and 10 months of use. The company’s press release is here. Some background on the study the data came from: Patients who weighed
READ THE FULL POST
October 6th 2010 | Biologics, Health care system, psoriatic arthritis, Public policy issues | 0 Comments
In what may be a look at the future of the U.S. health care system, the National Institute for Health and Clinical Excellence (NICE) in Britain has recommended denying psoriatic arthritis patients reimbursement for the biologic Simponi (golimumab) in the country’s government-run health care system. NICE has generated great controversy in the United States, with
READ THE FULL POST
October 5th 2010 | Biologics, Health care system, Insurance, Public policy issues | 0 Comments
New York Governor David Patterson recently signed many new measures into law, including one that could benefit psoriasis and psoriatic arthritis patients being treated with biologics: Among the bills signed by Governor Paterson is S.5000-B/A.8278-B, which will codify in law the currently regulatory authority of the State Insurance Department to disapprove requests from insurance carriers
READ THE FULL POST
August 15th 2010 | Biologics, Psoriasis Research, Treatment | 2 Comments
Even before it received U.S. Food and Drug Administration (FDA) approval in September 2009, Stelara (ustekinumab) had considerable buzz in the psoriasis community. Imagine a treatment that (after two initial doses) you take just four times a year! But the early buzz was based on 12 week, and later 40 week, studies. That left two
READ THE FULL POST
August 11th 2010 | Biologics, Patient Stories, psoriatic arthritis, Treatment | 0 Comments
The golf world was stunned yesterday by the news that superstar Phil Mickelson has been battling psoriatic arthritis this summer. He announced in a press conference that a severe flare of psoriatic arthritis had left him in a state where he “couldn’t move.” Read our full report on Phil Mickelson’s psoriatic arthritis.
|
|
|
